Avadomide - Celgene Coporation

Drug Profile

Avadomide - Celgene Coporation

Alternative Names: CC 122

Latest Information Update: 03 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics; Piperidones; Quinazolines
  • Mechanism of Action Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hepatocellular carcinoma
  • Phase I Glioblastoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 08 Jan 2018 Celgene plans a pivotal programme for Non-Hodgkin lymphoma in 2018
  • 09 Dec 2017 Safety data from a phase I trial in Diffuse large B-cell lymphoma presented at the Annual Meeting and the Exposition of American Society for Haematology (ASH-2017)
  • 20 Nov 2017 Avadomide is still in phase I trials for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA, Canada, France and Italy (NCT02031419)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top